Not available
Quote | Eli Lilly and Company (NYSE:LLY)
Last: | $906.71 |
---|---|
Change Percent: | 1.28% |
Open: | $902.71 |
Close: | $906.71 |
High: | $912 |
Low: | $878.5 |
Volume: | 4,526,566 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Eli Lilly and Company (NYSE:LLY)
2024-07-02 16:00:05 ET Terence Flynn from Morgan Stanley issued a price target of $1,023.00 for LLY on 2024-07-02 14:30:00. The adjusted price target was set to $1,023.00. At the time of the announcement, LLY was trading at $906.1521. The overall price target consensus i...
2024-07-02 13:54:29 ET More on Eli Lilly 5 Reasons Eli Lilly Just Keeps Rising Eli Lilly: Throwing Its Weight Around - But, For How Long? (Technical Analysis) Eli Lilly: The Party Is Probably Nearing The End Eli Lilly, Novo under pressure as Biden urges lower...
Message Board Posts | Eli Lilly and Company (NYSE:LLY)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $LLY News Article - Cramer dubs Lilly's Alzheimer's drug a 'holy grail' after today's d | whytestocks | investorshangout | 05/03/2023 7:05:51 PM |
whytestocks: $LLY News Article - Lilly to Participate in Bank of America Securities 2023 Healthcare | whytestocks | investorshangout | 05/03/2023 4:40:54 PM |
whytestocks: $LLY News Article - Lilly's Donanemab Significantly Slowed Cognitive and Functional Dec | whytestocks | investorshangout | 05/03/2023 4:35:50 PM |
whytestocks: $LLY News Article - Lilly Declares Second-Quarter 2023 Dividend | whytestocks | investorshangout | 05/01/2023 6:40:48 PM |
whytestocks: $LLY News Article - Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in 4/21 Morni | whytestocks | investorshangout | 04/21/2023 6:50:46 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 16:00:05 ET Terence Flynn from Morgan Stanley issued a price target of $1,023.00 for LLY on 2024-07-02 14:30:00. The adjusted price target was set to $1,023.00. At the time of the announcement, LLY was trading at $906.1521. The overall price target consensus i...
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's Disease PR Newswire Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its pivotal Phase 3 study and reduced participan...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...